Healthcare provider profile · identity verified

Ivan Eduardo Cichowicz, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Geriatric Psychiatry · BOCA RATON, FL · NPI 1932312840

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ivan Eduardo Cichowicz, M.D. received $87,533.38 in general payments during 2025 across 171 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 58.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 16 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Ingrezza, Lybalvi, Rexulti, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Austedo by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$87,533.38

171 reported records · 16 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$50,982.95	58.2%	65	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$35,023.94	40.0%	36	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$234.39	0.3%	13	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$230.34	0.3%	13	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$180.87	0.2%	7	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$175.08	0.2%	9	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$137.22	0.2%	6	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$118.17	0.1%	2	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$116.02	0.1%	5	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$83.19	0.1%	3	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$78.04	0.1%	3	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$73.21	0.1%	4	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$37.57	0.0%	2	2025
LivaNova USA, Inc.	Unresolved — no canonical attribution shown	$25.68	0.0%	1	2025
Almatica Pharma LLC	Unresolved — no canonical attribution shown	$20.38	0.0%	1	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$16.33	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$72,775.00	26
Consulting Fee	$5,500.00	2
Travel and Lodging	$4,722.22	15
Food and Beverage	$4,532.37	127
Education	$3.79	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$50,982.95	65	2025
Source payment records 2025-01-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.96 · Open Payments source 2025-01-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.65 · Open Payments source 2025-02-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.42 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.96 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.55 · Open Payments source 2025-04-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.79 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,980.00 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.17 · Open Payments source 2025-07-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.63 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.55 · Open Payments source 2025-07-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.94 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.63 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $111.02 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,151.73 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.64 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.90 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $61.80 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.88 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.09 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.09 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $402.97 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.95 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.89 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.65 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.67 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.69 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.00 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $203.17 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.06 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.95 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.75 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.71 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.35 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.01 · Open Payments source 2025-11-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.77 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.43 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.91 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.69 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$35,023.94	36	2025
Source payment records 2025-02-03 · Janssen Pharmaceuticals, Inc · $1,090.00 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $550.13 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $711.94 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $143.70 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $110.03 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $14.70 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $50.00 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $33.34 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $120.44 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $9.80 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $13.92 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $56.57 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $35.79 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $13.69 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $12.70 · Open Payments source 2025-02-22 · Janssen Pharmaceuticals, Inc · $20.53 · Open Payments source 2025-03-17 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-03-31 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-01 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-08 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-04-24 · Janssen Pharmaceuticals, Inc · $817.93 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $3,560.00 · Open Payments source 2025-05-01 · Janssen Pharmaceuticals, Inc · $146.74 · Open Payments source 2025-05-01 · Janssen Pharmaceuticals, Inc · $12,765.00 · Open Payments source 2025-05-02 · Janssen Pharmaceuticals, Inc · $24.30 · Open Payments source 2025-05-08 · Janssen Pharmaceuticals, Inc · $95.81 · Open Payments source 2025-05-14 · Janssen Pharmaceuticals, Inc · $3,560.00 · Open Payments source 2025-07-31 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-08-01 · Janssen Pharmaceuticals, Inc · $26.07 · Open Payments source 2025-08-26 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-08-26 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-09-13 · Janssen Pharmaceuticals, Inc · $33.60 · Open Payments source 2025-09-17 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-09-25 · Janssen Pharmaceuticals, Inc · $110.71 · Open Payments source 2025-09-30 · Janssen Pharmaceuticals, Inc · $3,560.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$253.12	12	2025
Source payment records 2025-01-17 · Otsuka America Pharmaceutical, Inc. · $10.81 · Open Payments source 2025-03-07 · Otsuka America Pharmaceutical, Inc. · $12.85 · Open Payments source 2025-05-02 · Otsuka America Pharmaceutical, Inc. · $22.37 · Open Payments source 2025-06-13 · Otsuka America Pharmaceutical, Inc. · $22.94 · Open Payments source 2025-07-11 · Otsuka America Pharmaceutical, Inc. · $23.39 · Open Payments source 2025-07-25 · Lundbeck LLC · $29.84 · Open Payments source 2025-08-01 · Otsuka America Pharmaceutical, Inc. · $14.30 · Open Payments source 2025-08-29 · Otsuka America Pharmaceutical, Inc. · $22.67 · Open Payments source 2025-10-17 · Lundbeck LLC · $31.27 · Open Payments source 2025-11-21 · Otsuka America Pharmaceutical, Inc. · $27.48 · Open Payments source 2025-12-05 · Otsuka America Pharmaceutical, Inc. · $18.27 · Open Payments source 2025-12-13 · Lundbeck LLC · $16.93 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$234.39	13	2025
Source payment records 2025-01-25 · Alkermes, Inc. · $18.59 · Open Payments source 2025-03-20 · Alkermes, Inc. · $6.86 · Open Payments source 2025-04-30 · Alkermes, Inc. · $8.44 · Open Payments source 2025-05-08 · Alkermes, Inc. · $3.79 · Open Payments source 2025-05-08 · Alkermes, Inc. · $21.12 · Open Payments source 2025-05-29 · Alkermes, Inc. · $28.58 · Open Payments source 2025-06-20 · Alkermes, Inc. · $21.28 · Open Payments source 2025-07-08 · Alkermes, Inc. · $21.10 · Open Payments source 2025-07-18 · Alkermes, Inc. · $20.66 · Open Payments source 2025-08-15 · Alkermes, Inc. · $27.31 · Open Payments source 2025-10-16 · Alkermes, Inc. · $13.43 · Open Payments source 2025-11-07 · Alkermes, Inc. · $24.68 · Open Payments source 2025-12-19 · Alkermes, Inc. · $18.55 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$230.34	13	2025
Source payment records 2025-01-10 · Neurocrine BioSciences, Inc. · $12.50 · Open Payments source 2025-03-14 · Neurocrine BioSciences, Inc. · $20.85 · Open Payments source 2025-05-07 · Neurocrine BioSciences, Inc. · $19.08 · Open Payments source 2025-05-30 · Neurocrine BioSciences, Inc. · $33.47 · Open Payments source 2025-06-06 · Neurocrine BioSciences, Inc. · $29.21 · Open Payments source 2025-07-25 · Neurocrine BioSciences, Inc. · $25.68 · Open Payments source 2025-08-05 · Neurocrine BioSciences, Inc. · $6.64 · Open Payments source 2025-08-09 · Neurocrine BioSciences, Inc. · $36.18 · Open Payments source 2025-09-05 · Neurocrine BioSciences, Inc. · $9.59 · Open Payments source 2025-09-05 · Neurocrine BioSciences, Inc. · $6.29 · Open Payments source 2025-11-07 · Neurocrine BioSciences, Inc. · $11.09 · Open Payments source 2025-11-07 · Neurocrine BioSciences, Inc. · $6.48 · Open Payments source 2025-11-18 · Neurocrine BioSciences, Inc. · $13.28 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$180.87	7	2025
Source payment records 2025-01-21 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $1.73 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $12.57 · Open Payments source 2025-07-07 · Teva Pharmaceuticals USA, Inc. · $9.96 · Open Payments source 2025-08-15 · Teva Pharmaceuticals USA, Inc. · $3.17 · Open Payments source 2025-08-15 · Teva Pharmaceuticals USA, Inc. · $11.10 · Open Payments source 2025-10-17 · Teva Pharmaceuticals USA, Inc. · $17.34 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$137.22	6	2025
Source payment records 2025-01-24 · Takeda Pharmaceuticals U.S.A., Inc. · $23.85 · Open Payments source 2025-03-14 · Takeda Pharmaceuticals U.S.A., Inc. · $19.07 · Open Payments source 2025-05-23 · Takeda Pharmaceuticals U.S.A., Inc. · $19.04 · Open Payments source 2025-06-13 · Takeda Pharmaceuticals U.S.A., Inc. · $22.05 · Open Payments source 2025-08-22 · Takeda Pharmaceuticals U.S.A., Inc. · $23.15 · Open Payments source 2025-09-26 · Takeda Pharmaceuticals U.S.A., Inc. · $30.06 · Open Payments source
KISUNLA Normalized: kisunla	Drug	Lilly USA, LLC	$118.17	2	2025
Source payment records 2025-07-22 · Lilly USA, LLC · $90.17 · Open Payments source 2025-09-24 · Lilly USA, LLC · $28.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$116.02	5	2025
Source payment records 2025-02-28 · E.R. Squibb & Sons, L.L.C. · $34.13 · Open Payments source 2025-05-09 · E.R. Squibb & Sons, L.L.C. · $19.33 · Open Payments source 2025-08-05 · E.R. Squibb & Sons, L.L.C. · $14.23 · Open Payments source 2025-10-24 · E.R. Squibb & Sons, L.L.C. · $22.50 · Open Payments source 2025-12-12 · E.R. Squibb & Sons, L.L.C. · $25.83 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$83.19	3	2025
Source payment records 2025-04-12 · Vanda Pharmaceuticals Inc. · $25.55 · Open Payments source 2025-07-10 · Vanda Pharmaceuticals Inc. · $26.14 · Open Payments source 2025-09-05 · Vanda Pharmaceuticals Inc. · $31.50 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$73.21	4	2025
Source payment records 2025-01-24 · ABBVIE INC. · $18.90 · Open Payments source 2025-04-15 · ABBVIE INC. · $14.34 · Open Payments source 2025-05-29 · ABBVIE INC. · $21.16 · Open Payments source 2025-07-18 · ABBVIE INC. · $18.81 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$64.98	4	2025
Source payment records 2025-03-20 · Alkermes, Inc. · $6.86 · Open Payments source 2025-04-30 · Alkermes, Inc. · $8.44 · Open Payments source 2025-05-29 · Alkermes, Inc. · $28.58 · Open Payments source 2025-07-08 · Alkermes, Inc. · $21.10 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$37.57	2	2025
Source payment records 2025-02-28 · Axsome Therapeutics, Inc. · $20.93 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $16.64 · Open Payments source
VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Normalized: vns therapy symmetry model 8103 generator	Device	LivaNova USA, Inc.	$25.68	1	2025
Source payment records 2025-06-21 · LivaNova USA, Inc. · $25.68 · Open Payments source
LOREEV XR Normalized: loreev xr	Drug	Almatica Pharma LLC	$20.38	1	2025
Source payment records 2025-04-04 · Almatica Pharma LLC · $20.38 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$16.33	1	2025
Source payment records 2025-03-07 · Collegium Pharmaceutical, Inc. · $16.33 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Auvelity auvelity	2025	Auvelity	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	41 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	38 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	101	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	41	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	41	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	38	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	38	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	101	30
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192	Austedo · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	413	89
Escitalopram Oxalate	Escitalopram Oxalate	289	90
Alprazolam	Alprazolam	262	61
Bupropion Xl	Bupropion Hcl	216	59
Aripiprazole	Aripiprazole	207	53
Trazodone Hcl	Trazodone Hcl	197	63
Lorazepam	Lorazepam	196	49
Venlafaxine Hcl Er	Venlafaxine Hcl	189	47
Quetiapine Fumarate	Quetiapine Fumarate	180	52
Vilazodone Hcl	Vilazodone Hcl	177	48
Fluoxetine Hcl	Fluoxetine Hcl	154	39
Duloxetine Hcl	Duloxetine Hcl	149	34
Bupropion Hcl Sr	Bupropion Hcl	128	41
Lamotrigine	Lamotrigine	120	36
Olanzapine	Olanzapine	107	30
Trintellix	Vortioxetine Hydrobromide	101	30
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	97	28
Sertraline Hcl	Sertraline Hcl	92	30
Gabapentin	Gabapentin	90	21
Mirtazapine	Mirtazapine	83	35
Diazepam	Diazepam	78	19
Donepezil Hcl	Donepezil Hcl	77	28
Lurasidone Hcl	Lurasidone Hcl	69	17
Zolpidem Tartrate	Zolpidem Tartrate	59	22
Lithium Carbonate Er	Lithium Carbonate	56	11
Amitriptyline Hcl	Amitriptyline Hcl	52	12
Citalopram Hbr	Citalopram Hydrobromide	51	15
Temazepam	Temazepam	49	13
Divalproex Sodium	Divalproex Sodium	47	14
Paroxetine Hcl	Paroxetine Hcl	46	12
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	45	13
Doxepin Hcl	Doxepin Hcl	45	suppressed
Buspirone Hcl	Buspirone Hcl	41	19
Caplyta	Lumateperone Tosylate	41	suppressed
Divalproex Sodium Er	Divalproex Sodium	39	13
Risperidone	Risperidone	39	suppressed
Rexulti	Brexpiprazole	38	suppressed
Dayvigo	Lemborexant	31	suppressed
Memantine Hcl Er	Memantine Hcl	25	suppressed
Eszopiclone	Eszopiclone	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Nuplazid	Pimavanserin Tartrate	21	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	19	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Austedo	Deutetrabenazine	16	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	16	suppressed
Lithium Carbonate	Lithium Carbonate	16	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	16	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	15	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	15	suppressed
Dexmethylphenidate Hcl	Dexmethylphenidate Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Asenapine Maleate	Asenapine Maleate	13	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	13	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Armodafinil	Armodafinil	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Ingrezza	Valbenazine Tosylate	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed
Vraylar	Cariprazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$87,533.38 · 171 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, Jornay PM, KISUNLA, LOREEV XR, LYBALVI, REXULTI, SPRAVATO, TRINTELLIX, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, VRAYLAR	10	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Auvelity play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error